

Todor Popov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/25162/publications.pdf>

Version: 2024-02-01

98
papers

8,334
citations

117625

34
h-index

45317

90
g-index

102
all docs

102
docs citations

102
times ranked

8451
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of the food allergy severity score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1545-1558.	5.7	19
2	Time course of disease characteristics in patients with severe allergic asthma starting treatment with omalizumab. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, , .	1.0	0
3	Exhaled Breath Temperature Home Monitoring to Detect NSCLC Relapse: Results from a Pilot Study. <i>BioMed Research International</i> , 2022, 2022, 1-7.	1.9	2
4	The roadmap for allergology in Europe: The European training requirements for the specialty of allergology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1588-1591.	5.7	4
5	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	2.4	6
6	Medical devices in allergy practice. <i>World Allergy Organization Journal</i> , 2020, 13, 100466.	3.5	7
7	Fractional exhaled breath temperature in patients with asthma, chronic obstructive pulmonary disease, or systemic sclerosis compared to healthy controls. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1747014.	1.5	9
8	International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants. <i>World Allergy Organization Journal</i> , 2020, 13, 100106.	3.5	94
9	Definition, aims, and implementation of GA ² LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	5.7	29
10	<p></p>In vitro and in vivo Evaluation of the Efficacy and Safety of Powder Hydroxypropylmethylcellulose as Nasal Mucosal Barrier<p></p>. <i>Medical Devices: Evidence and Research</i> , 2020, Volume 13, 107-113.	0.8	6
11	In vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2161-2169.	5.7	23
12	Food Allergy in Adults: Substantial Variation in Prevalence and Causative Foods Across Europe. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1920-1928.e11.	3.8	109
13	In-Vitro Setup to Test Hydroxy-Propyl-Methyl-Cellulose as Allergen Barrier over a Span of 360 Minutes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB193.	2.9	1
14	Powder Cellulose in Allergic Rhinitis Management: Relevance of in vitro Findings to Real-Life Safety. <i>International Archives of Allergy and Immunology</i> , 2019, 179, 17-18.	2.1	2
15	In vitro study of the adsorption of 2.5 µm particles (PM2.5) by hydroxy-propyl-methyl-cellulose powder (HPMC). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB24.	2.9	1
16	Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. <i>World Allergy Organization Journal</i> , 2019, 12, 100079.	3.5	2
17	<sc>ARIA</sc> pharmacy 2018 Allergic rhinitis care pathways for community pharmacy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
18	The roadmap for allergology in Europe: The subspecialty of allergology as a stop-over on the way to a full specialty. An EAACI position statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 540-548.	5.7	20

#	ARTICLE	IF	CITATIONS
19	Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 549-559.	5.7	60
20	Current practice of allergy diagnosis and the potential impact of regulation in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 323-327.	5.7	17
21	Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. <i>Journal of Pragmatic and Observational Research</i> , 2018, Volume 9, 29-42.	1.5	18
22	Benefits of Nasal Cellulose Powder Application Depend on the Type of Allergen Sensitization in Allergic Rhinitis. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 182.	2.9	0
23	The added value of exhaled breath temperature in respiratory medicine. <i>Journal of Breath Research</i> , 2017, 11, 034001.	3.0	20
24	A Double Blind Placebo Controlled Study Documenting the Effect of Nasally Applied Cellulose-Derived Powder in Subjects Sensitized to Grass Pollen. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB386.	2.9	1
25	Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1015-1024.e8.	3.8	82
26	Methyl-cellulose powder for prevention and management of nasal symptoms. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 885-892.	2.5	24
27	Blood eosinophil count and exacerbation risk in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700761.	6.7	64
28	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 92-104.	3.3	47
29	The oral CRTh2 antagonist QAW039 (feviprant): A phase II study in uncontrolled allergic asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 39, 54-63.	2.6	100
30	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	3.2	121
31	Real-Life Study on the Effect of Micronized Cellulose Powder As Add-on to Intranasal As-Needed Treatment of Subjects with Pollen Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB402.	2.9	4
32	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
33	Data on the oral CRTh2 antagonist QAW039 (feviprant) in patients with uncontrolled allergic asthma. <i>Data in Brief</i> , 2016, 9, 199-205.	1.0	1
34	Relationship Between Exhaled Breath Temperature and Ear Temperature in Otherwise Healthy Persons during Febrile Infectious Illness. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB202.	2.9	1
35	Exhaled breath temperature measurement: Applicability in childhood. <i>Pediatric Pulmonology</i> , 2016, 51, 91-92.	2.0	2
36	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	3.2	47

#	ARTICLE	IF	CITATIONS
37	Clinical characteristics of patients seeking medical advice for nasal symptoms in Bulgaria with special focus on children. <i>World Allergy Organization Journal</i> , 2016, 9, 11.	3.5	1
38	Budesonide/salmeterol in fixed-dose combination for the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 113-125.	2.5	2
39	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
40	A Single Breath Method to Assess the Relative Contribution of Central and Peripheral Airways to Overall Exhaled Breath Temperature. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB177.	2.9	1
41	Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 134-139.	2.2	14
42	Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. <i>World Allergy Organization Journal</i> , 2015, 8, 25.	3.5	328
43	Hazelnut allergy across Europe dissected molecularly: A EuroPrevall outpatient clinic survey. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 382-391.	2.9	92
44	Integrating Evidence for Managing Asthma in Patients Who Smoke. <i>Allergy, Asthma and Immunology Research</i> , 2014, 6, 114.	2.9	22
45	Frequent cough in unsatisfactory controlled asthma – results from the population-based West Sweden Asthma Study. <i>Respiratory Research</i> , 2014, 15, 79.	3.6	31
46	Biologic agents and the therapy of chronic spontaneous urticaria. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 347-353.	2.3	9
47	Objective approach for fending off the sublingual immunotherapy placebo effect in subjects with pollenosis: double-blinded, placebo-controlled trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 108-113.	1.0	4
48	A real life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough. <i>Cough</i> , 2014, 10, 2.	2.7	14
49	Night-time sedating H ₁ antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014, 171, 148-154.	1.5	58
50	Exhaled breath temperature: broadening the horizons [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 250-251.	1.2	4
51	Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 624-629.	2.6	28
52	Effect of montelukast for treatment of asthma in cigarette smokers. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 763-771.e6.	2.9	58
53	Kiwifruit allergy across Europe: Clinical manifestation and IgE recognition patterns to kiwifruit allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 164-171.	2.9	82
54	What we should learn from the London Olympics. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 1-3.	2.3	9

#	ARTICLE	IF	CITATIONS
55	Characteristics of a patient population seeking medical advice for nasal symptoms in Bulgaria. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 232-236.	1.0	6
56	Maintenance of Skills, Competencies, and Performance in Allergy and Clinical Immunology: Time to Lay the Foundation for a Universal Approach. <i>World Allergy Organization Journal</i> , 2012, 5, 45-51.	3.5	3
57	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1049-1062.	2.9	486
58	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA<sup>2</sup></sup>LEN – ARIA Position Paper. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 216-231.	2.1	83
59	Human exhaled breath analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 451-456.	1.0	161
60	Challenges in the Management of Chronic Urticaria. <i>World Allergy Organization Journal</i> , 2011, 4, S28-S31.	3.5	3
61	Challenges in the Management of Chronic Urticaria. <i>World Allergy Organization Journal</i> , 2011, 4, S28-S31.	3.5	6
62	Pooled analysis of studies on DNA adducts and dietary vitamins. <i>Mutation Research - Reviews in Mutation Research</i> , 2010, 705, 77-82.	5.5	13
63	Development and implementation of guidelines in allergic rhinitis – an ARIA – GA²/sup>LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1212-1221.	5.7	85
64	Temperatura do ar exalado, um novo biomarcador no controle da asma: um estudo piloto. <i>Jornal Brasileiro De Pneumologia</i> , 2010, 36, 693-699.	0.7	28
65	Daily Monitoring of Asthmatics by Means of Individual Devices for Exhaled Breath Temperature Measurement. <i>IEEE Sensors Journal</i> , 2010, 10, 44-48.	4.7	11
66	The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 676-682.	2.9	278
67	Development of an Individual Device for Exhaled Breath Temperature Measurement. <i>IEEE Sensors Journal</i> , 2010, 10, 110-113.	4.7	16
68	Exhaled Breath Temperature Measurement Made Easy. <i>Pediatric Allergy and Immunology</i> , 2009, 20, 200-201.	2.6	13
69	Effect of vitamin levels on biomarkers of exposure and oxidative damage – The EXPAH study. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 672, 129-134.	1.7	21
70	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 8-160.	5.7	3,827
71	The association of pet keeping at home with symptoms in airways, nose and skin among Bulgarian children. <i>Pediatric Allergy and Immunology</i> , 2008, 19, 702-708.	2.6	42
72	Genetic Susceptibility to Benzene Toxicity in Humans. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2008, 71, 1482-1489.	2.3	21

#	ARTICLE	IF	CITATIONS
73	Circadian Changes in the Sputum of Asthmatic Subjects and Healthy Controls. World Allergy Organization Journal, 2008, 1, 74-78.	3.5	6
74	Evaluation of a simple, potentially individual device for exhaled breath temperature measurement. Respiratory Medicine, 2007, 101, 2044-2050.	2.9	76
75	Role of GSTT1 deletion in DNA oxidative damage by exposure to polycyclic aromatic hydrocarbons in humans. International Journal of Cancer, 2007, 120, 2499-2503.	5.1	30
76	Effects of polycyclic aromatic hydrocarbons (PAHs) in environmental pollution on exogenous and oxidative DNA damage (EXPAH project): Description of the population under study. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 1-6.	1.0	46
77	Effects of metabolic genotypes on intermediary biomarkers in subjects exposed to PAHs: Results from the EXPAH study. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 7-15.	1.0	18
78	Biomarkers of exposure to carcinogenic PAHs and their relationship with environmental factors. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 16-21.	1.0	34
79	Influence of PAHs in ambient air on chromosomal aberrations in exposed subjects: International study "EXPAH". Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 41-48.	1.0	5
80	Chromosomal aberrations by fluorescence in situ hybridization (FISH) - Biomarker of exposure to carcinogenic PAHs. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 62-70.	1.0	13
81	Effects of environmental air pollution on endogenous oxidative DNA damage in humans. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 71-82.	1.0	53
82	The relationship between biomarkers of oxidative DNA damage, polycyclic aromatic hydrocarbon DNA adducts, antioxidant status and genetic susceptibility following exposure to environmental air pollution in humans. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 83-92.	1.0	109
83	Sensitivity of different endpoints for in vitro measurement of genotoxicity of extractable organic matter associated with ambient airborne particles (PM10). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 103-113.	1.0	16
84	Exposure to environmental polycyclic aromatic hydrocarbons: Influences on cellular susceptibility to DNA damage (sampling KoÅšice and Sofia). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 145-154.	1.0	23
85	A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflammation Research, 2006, 55, 241-244.	4.0	41
86	The use of S-phenylmercapturic acid as a biomarker in molecular epidemiology studies of benzene. Chemico-Biological Interactions, 2005, 153-154, 97-102.	4.0	28
87	Biomarkers of exposure and effect in Bulgarian petrochemical workers exposed to benzene. Chemico-Biological Interactions, 2005, 153-154, 247-251.	4.0	13
88	Specific immune responses in workers exposed to benzene. International Immunopharmacology, 2005, 5, 1554-1559.	3.8	11
89	Molecular epidemiology studies of carcinogenic environmental pollutants. Mutation Research - Reviews in Mutation Research, 2003, 544, 397-402.	5.5	165
90	Cytogenetic effects of hexavalent chromium in Bulgarian chromium platers. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 514, 29-38.	1.7	71

#	ARTICLE	IF	CITATIONS
91	Possibilities to control the health risk of petrochemical workers. International Archives of Occupational and Environmental Health, 2002, 75, 21-26.	2.3	32
92	Assessment of the correlation between exposure to benzene and urinary excretion of t, t -muconic acid in workers from a petrochemical plant. International Archives of Occupational and Environmental Health, 2002, 75, 97-100.	2.3	18
93	Comparison of the clinical efficacy of standard and mucoadhesive-based nasal decongestants. British Journal of Clinical Pharmacology, 2002, 53, 107-109.	2.4	8
94	Monitoring of fluctuating airway obstruction and episodes of coughing by thoracic electrical impedance. Journal of Medical Engineering and Technology, 2001, 25, 49-52.	1.4	1
95	Occupational exposure to Cr(VI): comparison between chromium levels in lymphocytes, erythrocytes, and urine. International Archives of Occupational and Environmental Health, 1996, 69, 39-44.	2.3	31
96	DNA-protein crosslinks in peripheral lymphocytes of individuals exposed to hexavalent chromium compounds. Biomarkers, 1996, 1, 86-93.	1.9	41
97	Spontaneous and induced sputum to measure indices of airway inflammation in asthma.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 866-869.	5.6	212
98	Some technical factors influencing the induction of sputum for cell analysis. European Respiratory Journal, 1995, 8, 559-65.	6.7	84